TY - JOUR
T1 - Cisplatin in recurrent pediatric brain tumors A pog phase II study a pediatric oncology group study
AU - Sexauer, Charles L.
AU - Khan, Atiya
AU - Burger, Peter C.
AU - Krischer, Jeffrey P.
AU - Van Eys, Jan
AU - Vats, Tribhawan
AU - Ragab, Abdelsalam H.
PY - 1985/10/1
Y1 - 1985/10/1
N2 - Forty‐six evaluable pediatric patients with primary recurrent brain tumors resistant to standard therapy were treated with cisplatin, 60 mg/m2/day, X2 days every 3 to 4 weeks, to study the efficacy and toxicity of this drug. Complete and partial responses, documented by computed tomography (CT) scan, were demonstrated in 4 of 10 patients with medulloblastoma and 3 of 15 patients with ependymoma. No activity was documented in astrocytic tumors. Dose limiting major toxicities were renal and auditory. It is recommended that the new analogues of cisplatin with less toxicity be studied in these tumors.
AB - Forty‐six evaluable pediatric patients with primary recurrent brain tumors resistant to standard therapy were treated with cisplatin, 60 mg/m2/day, X2 days every 3 to 4 weeks, to study the efficacy and toxicity of this drug. Complete and partial responses, documented by computed tomography (CT) scan, were demonstrated in 4 of 10 patients with medulloblastoma and 3 of 15 patients with ependymoma. No activity was documented in astrocytic tumors. Dose limiting major toxicities were renal and auditory. It is recommended that the new analogues of cisplatin with less toxicity be studied in these tumors.
UR - http://www.scopus.com/inward/record.url?scp=0021926013&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021926013&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19851001)56:7<1497::AID-CNCR2820560703>3.0.CO;2-7
DO - 10.1002/1097-0142(19851001)56:7<1497::AID-CNCR2820560703>3.0.CO;2-7
M3 - Article
C2 - 4040799
AN - SCOPUS:0021926013
SN - 0008-543X
VL - 56
SP - 1497
EP - 1501
JO - Cancer
JF - Cancer
IS - 7
ER -